Clinical trial

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

NCT05438810

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2022-01-18

PhasePHASE3

Study timeline

Study start (actual)2022-01-18Date precision: day

Registry last updated2022-07-05

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Advanced Breast Cancerunresolved

Female Breast Cancerunresolved

Interventions

FCN-437c,Fulvestrant,Goserelin acetateDRUG

Placebo,Fulvestrant,Goserelin acetateDRUG

Sponsors & collaborators

Ahon Pharmaceutical Co., Ltd.lead sponsor

Mapped research locations

ShanghaiShanghai Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05438810 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.